Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials

Introduction To assess the efficacy and safety profile of the dipeptidyl-peptidase-4 inhibitor sitagliptin in a population of self-identified Hispanic/Latino patients with type 2 diabetes. Methods Data were pooled from ten randomized, double-blind studies in which subjects were treated with sitaglip...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes therapy 2018-08, Vol.9 (4), p.1581-1589
Main Authors: Raji, Annaswamy, Long, Jianmin, Lam, Raymond L. H., O’Neill, Edward A., Engel, Samuel S.
Format: Article
Language:English
Subjects:
Cardiology
Clinical trials
Diabetes
Drug therapy
Effectiveness
Endocrinology
Evidence-based medicine
Glucose
Glucose monitoring
Hemoglobin
Hispanic Americans
Hypoglycemia
Insulin
Internal Medicine
Medicine
Medicine & Public Health
Original Research
Quantitative analysis
Side effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction To assess the efficacy and safety profile of the dipeptidyl-peptidase-4 inhibitor sitagliptin in a population of self-identified Hispanic/Latino patients with type 2 diabetes. Methods Data were pooled from ten randomized, double-blind studies in which subjects were treated with sitagliptin 100 mg/day (as mono- or combination therapy) or placebo, and used to evaluate the glycemic efficacy, safety, and tolerability of sitagliptin compared with placebo after 24 weeks of treatment. Results A total of 804 Hispanic/Latino patients were included in the analysis. Baseline characteristics in the treatment groups were similar (mean baseline HbA1c of approximately 8.5%). The LS mean HbA1c changes from baseline were − 0.94% with sitagliptin and − 0.32% with placebo, and the between-group difference was − 0.62%, p  
ISSN:1869-6953
1869-6961
DOI:10.1007/s13300-018-0461-x